Accenture initiated with a Buy at Truist

Truist initiated coverage of Accenture (ACN) with a Buy rating and $317 price target Accenture provides a relatively attractive, though not risk-free, way to gain exposure to enterprise modernization driven by GenAI, offering mid-single-digit growth and stable margins at a reasonable valuation that is discounted versus its history, the analyst tells investors in a research note. Despite near-term cannibalization concerns, strategic partnerships and a strong track record of adapting legacy revenue position patient investors for potential upside, the firm says.